Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Axatilimab in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05723055Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in classical Hodgkin lymphoma (cHL), sponsored by University of Utah. Started May 2023; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05723055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723055.